The Synbias-Gemini leadership team is composed of experienced professionals with deep expertise in the pharmaceutical and chemical industries. Their collective background spans strategic management, quality assurance, research and development, regulatory affairs, and sales and marketing. Together, they drive the organization's strategic initiatives, ensuring operational excellence, innovation, and sustainable growth. This team brings a practical yet forward-thinking approach, fostering collaboration and maintaining a strong commitment to delivering high-quality, compliant products to meet global market demands.
Giles Farley serves primarily as the Chairman of Synbias Pharma AG. In addition, he holds the interim position of CEO of Synbias Pharma AG and Managing Director at Gemini PharmChem Mannheim GmbH, where he oversees the group's strategic direction, developments, and growth initiatives.
With over 25 years of experience in investment and finance, Giles brings a wealth of expertise in private equity, venture capital, and corporate finance. As a partner at FPP Asset Management since 2017, he has served as Director of Private Equity, managing investments in the pharmaceuticals, healthcare, food & beverage, and technology sectors. Synbias Pharma AG, a portfolio company of FPP, benefits from his strategic leadership and vision.
Earlier in his career, Giles held key leadership roles at Ridge End Capital and ARTA Investment Partners, managing transactions and restructuring projects totaling over $1 billion. He has also served as Vice President at Citibank Germany and held senior roles within Citigroup's corporate leadership program.
Giles began his career at The Boston Consulting Group and Dialogue Capital Management, a US-based hedge fund. He holds an MBA from Stanford Graduate School of Business and a BA in Political Science from UCLA. His leadership ensures Synbias-Gemini Group's continued innovation and expansion in the global pharmaceutical market.
Iryna Fedortsova is a Board Director at Synbias Pharma AG and the Finance and Administration Director of Gemini PharmChem Mannheim GmbH. With over 18 years of experience across finance, operations, HR, and development strategy, she has led impactful initiatives in dynamic and challenging environments, including more than 14 years in senior management roles.
A recognized expert in crisis and turnaround management, Iryna has successfully restructured top management teams, implemented effective processes, and cultivated corporate cultures that drive sustainable growth and stability. Her background includes Ernst & Young as a career start and pivotal roles at 1+1 Media Holding, the largest media company in Ukraine. She also serves as a non-executive advisor and director to multiple companies across various industries.
Iryna excels in establishing finance departments and developing comprehensive processes and policies that enhance efficiency across organizations. As a seasoned business advisor, she has delivered rapid business analyses, achieving short-term transformation goals while ensuring strategic, long-term success.
Her academic credentials include an Executive MBA from Oxford University, and she is an ACCA-certified professional. Iryna's strategic vision, practical leadership, and proven track record continue to drive the growth and success of Synbias-Gemini Group.
Dr. Sabine Corr brings over 23 years of experience in the pharmaceutical and chemical industries, holding key positions in Quality Assurance, Quality Control, and Regulatory Affairs. She holds a PhD in Chemistry and has served in various leadership roles, including as a member of the board of directors at BioChem, a company providing QA, QC, and regulatory services to global and medium-sized pharmaceutical and chemical firms.
Since 2014, Dr. Corr has been leading Quality Assurance, Quality Control, and Regulatory Affairs at Gemini PharmChem Mannheim GmbH. She is responsible for overseeing all aspects of quality management, ensuring that the company's Active Pharmaceutical Ingredients (APIs) meet the stringent requirements of cGMP and expectation of global regulatory bodies such as German authority, FDA, ANVISA and Swissmedic. Her expertise spans API release, regulatory compliance, quality system development, and ensuring adherence to industry best practices.
Dr. Corr's leadership has been instrumental in maintaining the high standards of Synbias-Gemini's production facilities, which are designed for the development and manufacturing of highly potent APIs. She also ensures compliance with environmental and safety regulations, such as the "zero-emission concept", supporting the company's commitment to sustainability and excellence in pharmaceutical manufacturing.
Elena Kalafat holds a degree in chemistry and brings over 21 years of experience in the pharmaceutical industry, having held key positions such as Head of Quality Assurance and Head Regulatory, with a primary focus on Active Pharmaceutical Ingredients (APIs). Since 2016, she has served as the Head of Regulatory at Gemini PharmChem Mannheim GmbH and Synbias Pharma AG.
Elena's expertise has been instrumental in successfully registering Synbias-Gemini's APIs across all continents, ensuring global regulatory compliance and supporting the company's ambitious growth goals. She plays a pivotal role in assisting Synbias-Gemini's customers in filing their own products, helping them navigate complex regulatory landscapes and facilitating smooth product approvals. With a strong background in quality assurance and regulatory affairs, Elena ensures that Synbias-Gemini maintains the highest standards in all aspects of API development, from initial regulatory submissions to lifecycle management.
Dr. Illia Kapitanov is an expert in pharmaceutical, analytical, organic, physical, and colloid chemistry with a strong academic and industrial background, bringing over 15 years of experience in Quality Control (QC) and Research & Development (R&D). His expertise spans multiple countries, including Germany, Estonia, France, Russia, and Ukraine. Dr. Kapitanov has extensive experience supporting GMP-compliant industrial API production across all phases, from project development to commercial sales.
Dr. Kapitanov joined the Gemini PharmChem Mannheim GmbH team in 2019 after completing his mission as a senior researcher in the project VFP655 "Excellent Tallinn University of Technology Research Chair in Green Chemistry and Technology" (EU 7th Framework Programmes). He now leads the Quality Control department and spearheads the company's collaboration with EU academic institutions, further enhancing the company's research and technological capabilities in the API sector.
Dr. Iaroslav Matviienko is an experienced professional with 19 years in the pharmaceutical industry, currently serving as the Head of Production and Deputy Managing Director at Gemini PharmChem in Germany. He began his career with the Synbias-Gemini Group in Ukraine, where he led the R&D team and managed the Laboratory of Chemistry and Medicines.
In 2014, Dr. Matviienko joined Gemini PharmChem Mannheim GmbH in Germany, progressing from Head of R&D to Head of Production. In this role, he has been responsible for overseeing the development, validation, and production of new APIs, ensuring compliance with GMP, FDA, and global regulatory standards. Since 2022, he has also taken on the role of Deputy Managing Director, where he focuses on strategic planning, cost optimization, and operational efficiency. Dr. Matviienko's achievements include developing over 30 products, automating production processes, and significantly improving labor productivity while driving innovation and growth within the company. He is currently obtaining an MBA in International Healthcare Management from the Frankfurt School of Finance and Management, further enhancing his expertise in strategic planning and operational efficiency within the pharmaceutical sector.
Dr. Markus Melcher holds a PhD in inorganic chemistry and brings over 24 years of international experience in the pharmaceutical and chemical industries. Since joining Gemini PharmChem Mannheim GmbH in 2017, he has served as the Head of QA-Qualification/Validation and Head of Health, Safety, and Environment (HSE).
Before joining the company, Dr. Melcher held leadership roles in Quality Control at various companies, including BioChem GmbH, HWI Analytik GmbH, Senn Chemicals AG, BAG Health Care GmbH, and Corden Pharma GmbH. Additionally, he worked as a Quality Assurance Manager GMP/GLP/GCLP, where he played a key role in setting up a control laboratory under GCLP conditions at a biotechnology company, Cytonet GmbH & Co KG.
In his current role at Synbias-Gemini Group, Dr. Melcher is responsible for ensuring compliance with the highest standards of safety and environmental management, aligning HSE practices with GMP and regulatory requirements, and overseeing the qualification of devices and validation of processes to maintain product quality and safety in the company's highly potent API production.
Uliana Saldan is the Head of Sales, Marketing, and Customer Experience at Synbias-Gemini Group. Since joining Synbias Pharma AG in 2014, she has played a pivotal role in driving sales growth, expanding the company's market presence, and ensuring exceptional customer satisfaction. In her current role, Uliana develops and executes sales strategies, manages key client relationships, and oversees marketing initiatives. Her responsibilities include pricing strategy, market research, and identifying opportunities for new API development.
With fluency in Ukrainian, Russian, Italian, and English, Uliana brings a diverse and international perspective, having previously worked in fashion and food & beverage industries. She continues to enhance her professional expertise through various industry-related training programs of European Compliance Academy. She is currently pursuing an MBA in International Healthcare Management from the Frankfurt School of Economics, strengthening her strategic and leadership capabilities in the pharmaceutical industry.
Olha Shelkovenko holds a degree in Pedagogy from Ukraine and a degree in Applied Translation and Cultural Studies from Johannes Gutenberg University Mainz in Germersheim, Germany. After working as a freelance lecturer and translator for many years, she transitioned into Human Resources and Administration at Gemini PharmChem Mannheim GmbH in 2020.
In addition to her diverse background, Olha is committed to her professional growth, regularly attending various HR courses and development programs to stay updated on best practices and evolving trends in human resource management. Her continuous learning approach ensures that she brings the latest knowledge and strategies to her role, enhancing recruitment, employee development, and organizational efficiency. This dedication to self-improvement has been crucial in managing the diverse workforce and supporting the company's mission of producing high-quality Active Pharmaceutical Ingredients (APIs).
Dr. Volodymyr Sypchenko holds a Master's Degree and PhD in Organic Chemistry from Kyiv Taras Shevchenko National University, Ukraine. Since starting his career at Gemini PharmChem Mannheim GmbH in 2014, he has progressed to become the Head of Research & Development in 2022.
Dr. Sypchenko is a highly experienced process development and project management professional, with more than 10 years of experience in the pharmaceutical industry. He plays a critical role in driving innovation at Synbias-Gemini Group, leading R&D efforts to expand the company's API portfolio optimize routes of synthesis and production processes. His work ensures that Synbias-Gemini remains at the forefront of API route synthesis, including the development of new oncology-related products and strategic collaborations with global pharmaceutical companies.
Our website uses only essential cookies that are necessary for its proper functioning. We do not use cookies for tracking or advertising purposes. For more details, please refer to our Privacy policy.